Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years

Lupus

Volumn 18, Issue 6, 2009, Pages 516-521

  Posalski, J D ^a   Ishimori, M L ^a   Wallace, D J ^a   Weisman, Michael H ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Extra renal; Haematologic changes; Musculoskeletal; Mycophenolate mofetil; Renal lupus; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; B CELL ACTIVATING FACTOR; CD40 LIGAND; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; GLATIRAMER; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRASTERONE; PREDNISONE; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPTIC SHOCK; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VASCULITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALIFORNIA; CHILD; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; MYCOPHENOLIC ACID; RESPIRATORY TRACT DISEASES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASCULITIS; YOUNG ADULT;

EID: 65149101180     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308099471     Document Type: Article

References (21)

1. McCune W, Marder W, Riskalla M. Immunosuppressive drug therapy. Philadelphia: Lippincott Williams & Wilkins; 2007 [Chapter 61].
2. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999; 26: 1275-1279.
3. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78: 44-49.
4. Silman AJ, Petrie J, Hazleman B, Evans SH. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study. Ann Rheum Dis 1988; 47: 988-992.
5. Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT. Risk of acute pancreatitis in users of azathioprine: A population-based case-control study. Am J Gastroenterol 2003; 98: 1305-1308.
6. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford) 1999; 38: 640-644.
7. Shaye OA, Yadegari M, Abreu MT. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 2007; 102: 2488-2494.
8. Ginzler E, Dooley M, Aranow C. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
9. Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: Mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005; 14: S33-s38.
10. Ginzler E; Appel G; Dooley MA;. Mycophenolate mofetil and intravenous cyclophosphamide in the aspreva lupus management study (ALMS): Efficacy by racial group. ACR Boston: L13, 2007.
11. Mok C. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: As systematic review. Scand J Rheumatol 2007; 36: 329-337.
12. Kiani A, Akhter E, Magder L, Petri M. Effect of Mycophenolate Mofetil (MMF) on Cutaneous and Serositis Manifestations of SLE. Arthritis Rheum 2007; 56: S457-S458 [abstracts].
13. Alba P, Karim M, Hunt B. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003; 12: 633-635.
14. Mak A, Mok C. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005; 14: 856-858.
15. Vasoo S, Thumboo J, Fong K. Refractory immune thrombocytopenia in systemic lupus erythematosus: Response to mycophenolate mofetil. Lupus 2003; 12: 630-632.
16. D'Cruz D. Mycophenolate mofetil in systemic vasculitis. Lupus 2005; 14: s55-s57.
17. Moder KG, Amin S, Mazlumzadeh M, Crowson C, Ytterberg S. The effect of mycophenolate mofetil on patients with active non-renal SLE. Clin Exp Rheumatol 2007; 25: 932.
18. Karim M, Alpa P, Cuadrado M. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 2002; 41: 876-882.
19. Pisoni C, Karim Y, Cuadrado M. Mycophenolate mofetil and systemic lupus erythematosus: An overvSew. Lupus 2005; 14: s9-s11.
20. Pisoni C, Sanchez F, Karim Y. Mycophenolate mofetil in systemic lupus erythematosus: Efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047-1052.
21. Nannini C, Crowson C, Matteson E, Moder K. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients. ACR/ARHP program book supplement. Late-Breaking and Fellows-in-training 2007; F90: 60-61[abstracts].